巨头赛诺菲:Dupilumab业绩高涨94%;过专利药物迎来黄昏
2023-08-05 22:00
举报
Dupixent(IL-4R a)业绩为16.34亿欧元,同比大增93.8%;Praluent(PCSK9)业绩仅为1.46亿欧元,同比增长18%;波立维Plavix业绩为5....
相关阅读
2021-09-13
2021-09-30
2021-11-18
2023-03-08
2021-08-26
2023-02-06
2022-12-26
2021-09-26
2021-12-03
2021-09-06
2022-12-22
2021-11-01
